Description of the medicine: Medrotestron propionate (Medrotestroni propionas)
MEDROTESTRON PROPIONATE (Medrotestroni propionas). 2-a-Methyl-5 a -androstanol-17 b -one-3-propionate, or 2-a-methyldihydrotestosterone.
Synonyms: Dromostanolon propionate, Drostanoloni propionas, Emdisterone, Masterid, Masteni, Masteron, Mastisol, Metormon, Permastil, Prometholone, etc.
White crystalline powder. It is practically insoluble in water, soluble in alcohol, slowly soluble in vegetable oils.
By structure and action, it is close to testosterone propionate; It has less androgenic effect and has a higher anabolic activity. It has an antitumor effect in breast cancer.
They are mainly used in advanced cases of breast cancer with metastases. Assign to patients with a preserved menstrual cycle or with menopause up to 5 years, as well as patients in whom ovarian function is suppressed by previous receipt or who underwent ovariectomy; the drug is more effective after bilateral ovariectomy.
Medrotestron is administered intramuscularly daily: during active metastasis - 0.1 g per day, with remission - 0.05 g per day. Apply the drug for a long time.
When prescribing the drug, one should take into account the possibility of developing hypercalcemia and hypercalciuria, acute parenchymal hepatitis with jaundice, cardiac disturbances, virilization phenomena. If side effects occur, the injection is temporarily discontinued.
The drug is contraindicated in acute diseases of the liver and kidneys, cardiovascular system, with hypercalcemia, as well as in the terminal stage of the disease.
Release form: 5% oil solution in ampoules of 1 ml (Solutio Medrotestroni propionatis oleosa 5% рro injectionibus) - a clear oily liquid of light yellow color.
Storage: List B. At room temperature.